For fiscal 2025, Knight has increased its financial guidance on revenues and now expects to generate between $410 million to $420 million in revenues up from $390 to $405 million. The adjusted EBITDA is expected to be approximately 13% of revenues. The increase in our revenues outlook is driven by the better performance in the first half of the year and the incremental revenues from the Sumitomo Transaction.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KHTRF:
- Knight Therapeutics announces CREXONT regulatory submission in Mexico
- Knight Therapeutics announces CREXONT NDS accepted for Health Canada review
- Knight Therapeutics closes acquisition of Paladin
- Knight Therapeutics Secures US$50 Million Credit Facility to Fuel Growth
- Knight Therapeutics closes $50M revolving credit facility